India’s fight against obesity is gaining traction as the anti-obesity drug market has experienced explosive growth over the past five years, expanding more than fourfold to reach ₹576 crore by March 2025. This remarkable increase is primarily attributed to rising lifestyle diseases paired with a newfound willingness among consumers to invest in weight-loss treatments.
The growth of the anti-obesity drug segment is underscored by the significant market presence of semaglutide, marketed under the brand name Rybelsus by Danish pharmaceutical giant Novo Nordisk. This oral medication currently holds a commanding 69% share, generating ₹397 crore in sales—a notable jump from just ₹11 crore in March 2022. Semaglutide functions by mimicking a hormone that promotes feelings of fullness, therefore aiding in weight management.
The burgeoning acceptance of weight-loss medications among the Indian populace is also bolstered by the recent introduction of new treatment options. Eli Lilly’s Mounjaro (tirzepatide), a once-weekly injectable drug, has garnered attention for its efficacy in reducing body weight by up to 20%. Priced at around ₹3,500 per injection, Mounjaro has emerged as a financially feasible option for many looking to combat obesity.
As adults in India increasingly grapple with obesity—affecting nearly 100 million individuals—this segment is crucial not only for personal health but also for addressing related comorbid conditions such as type 2 diabetes and cardiovascular disease.
While semaglutide and tirzepatide remain at the forefront, other medications are also making their mark on the market. Drugs such as orlistat, dulaglutide, and liraglutide are notable players, with market valuations of ₹72 crore and ₹34 crore, respectively. These alternatives further enhance the treatment landscape, providing patients with various choices based on their specific weight management needs and medical histories.
Despite the increased popularity and efficacy of these medications, healthcare professionals emphasize that they should be paired with lifestyle modifications. Sustainable weight loss often necessitates a combination of medication and behavioural changes, including dietary management and increased physical activity.
Experts assert that medications alone cannot solve the obesity epidemic. Dr. Anjali Mehta, a leading endocrinologist in Mumbai, states, “While these drugs are effective, they are not a standalone solution. Encouraging a healthy lifestyle is paramount for achieving long-term results.”
-Raja Aditya
